Laverock Therapeutics at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Laverock Therapeutics brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on gene silencing that switches on with a cell's own activation state. Topics include programmable microRNA silencing in macrophages derived from stem cells for solid tumours and dynamic checkpoint silencing paired with CAR expression in T cells.
| Organization | ESGCT 2026 Attendance |
|---|---|
Laverock Therapeutics London, UK | |
Engineers cell therapies with programmable gene silencing that responds to a cell's state, including CAR-T and iPSC-derived macrophage programs. | Poster Thu Oct 29 2:00pm–4:00pm (Re)programmed to resist: Programmable silencing microRNA enables IPSC‑macrophages (iMAC) for solid tumour immunotherapy Poster Thu Oct 29 2:00pm–4:00pm Harnessing activation‑induced miRNAs for dynamic checkpoint silencing and CAR expression to improve the anti-tumour activity of CAR T cells |
Instantly find 20 buyers from Laverock Therapeutics
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction